Rate of non-medical use of RX pain meds 4.6 percent
January 10, 2013 in Medications
The rate of non-medical use of prescription pain relievers in the past year among individuals aged 12 years and older is estimated at 4.6 percent nationally, with considerable variation between states, according to a study published online Jan. 8 by the Substance Abuse and Mental Health Services Administration.
(HealthDay)—The rate of non-medical use of prescription pain relievers in the past year among individuals aged 12 years and older is estimated at 4.6 percent nationally, with considerable variation between states, according to a study published online Jan. 8 by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Researchers from SAMHSA in Rockville, Md., surveyed individuals aged 12 years or older regarding their non-medical use of prescription pain relievers during the past year.
The researchers found that, based on combined data from 2010 and 2011, the rate of past year non-medical use of prescription pain relievers was 4.6 percent nationally, and ranged from 3.6 percent in Iowa to 6.4 percent in Oregon. Seven of the 10 states with the highest rates of past year non-medical prescription pain reliever use were in the West region, while of the 10 states with the lowest rates, four were in the Midwest and four in the South. In 10 states, there was a decrease in past year non-medical use of prescription pain relievers among individuals aged 12 or older from combined 2009-2010 to 2010-2011 data.
"Addressing prescription drug misuse remains a top public health priority, as we've seen inconsistent progress in addressing the issue across the states," Pamela S. Hyde, J.D., a SAMHSA administrator, said in a statement. "Data from this report helps [us] better understand geographic variations in use and should help with the development of more targeted and effective prevention and treatment programs."
More information: More Information
Copyright © 2013 HealthDay. All rights reserved.
-
SAMHSA: Prevalence of mental illness in U.S. stable in 2011
Dec 05, 2012 |
not rated yet |
0
-
Depression triples between ages 12 and 15 in girls in U.S.
Jul 31, 2012 |
not rated yet |
0
-
Study suggests mid-adolescence is peak risk for extramedical use of pain relievers by young people
May 07, 2012 |
not rated yet |
0
-
Mental illness tied to higher rates of physical problems: report
Apr 13, 2012 |
not rated yet |
0
-
More than half of Americans drink alcohol: report
Aug 01, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Help at hand for people with schizophrenia
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
